

Chromosome-Encoded AmpC and CTX-M Extended-Spectrum β -Lactamases in Clinical Isolates of *Proteus mirabilis* from Korea

Wonkeun Song, Juwon Kim, Il Kwon Bae, Seok Hoon
Jeong, Young Hee Seo, Jong Hee Shin, Sook Jin Jang,
Young Uh, Jeong Hwan Shin, Mi-Kyung Lee and Kyungwon
Lee

Antimicrob. Agents Chemother. 2011, 55(4):1414. DOI:
10.1128/AAC.01835-09.

Published Ahead of Print 31 January 2011.

Updated information and services can be found at:
<http://aac.asm.org/content/55/4/1414>

These include:

REFERENCES

This article cites 23 articles, 15 of which can be accessed free
at: <http://aac.asm.org/content/55/4/1414#ref-list-1>

CONTENT ALERTS

Receive: RSS Feeds, eTOCs, free email alerts (when new
articles cite this article), [more»](#)

Information about commercial reprint orders: <http://journals.asm.org/site/misc/reprints.xhtml>
To subscribe to to another ASM Journal go to: <http://journals.asm.org/site/subscriptions/>

Chromosome-Encoded AmpC and CTX-M Extended-Spectrum β -Lactamases in Clinical Isolates of *Proteus mirabilis* from Korea[∇]

Wonkeun Song,¹ Juwon Kim,² Il Kwon Bae,² Seok Hoon Jeong,^{2*} Young Hee Seo,²
Jong Hee Shin,³ Sook Jin Jang,⁴ Young Uh,⁵ Jeong Hwan Shin,⁶
Mi-Kyung Lee,⁷ and Kyungwon Lee²

Department of Laboratory Medicine, Hallym University College of Medicine,¹ Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine,² and Department of Laboratory Medicine, Chung-Ang University College of Medicine,⁷ Seoul, Department of Laboratory Medicine, Chonnam National University Medical School,³ and Department of Laboratory Medicine, Chosun University Medical School,⁴ Gwangju, Department of Laboratory Medicine, Yonsei University Wonju College of Medicine, Wonju,⁵ and Department of Laboratory Medicine, Inje University College of Medicine, Busan,⁶ Republic of Korea

Received 29 December 2009/Returned for modification 14 March 2010/Accepted 16 January 2011

Among 222 *Proteus mirabilis* clinical isolates collected from 17 hospitals in Korea in 2008, 28 (12.6%) and 8 (3.6%) isolates exhibited extended-spectrum β -lactamase (ESBL) and AmpC phenotypes, respectively. The most common type of ESBL gene identified by PCR and sequencing experiments was *bla*_{CTX-M-14a} (*n* = 12). The *bla*_{CTX-M-90} (*n* = 4), *bla*_{CTX-M-15} (*n* = 3), *bla*_{CTX-M-12} (*n* = 3), *bla*_{CTX-M-2} (*n* = 2), *bla*_{CTX-M-14b} (*n* = 1), *bla*_{TEM-52} (*n* = 5), and *bla*_{SHV-12} (*n* = 1) genes were also detected. Eight isolates carried an AmpC β -lactamase gene, such as *bla*_{CMY-2} (*n* = 6) or *bla*_{DHA-1} (*n* = 2). All *bla* genes encoding CTX-M-1- and CTX-M-9-type enzymes and all *bla*_{CMY-2} genes were preceded by *ISEcp1*-like elements. The *bla*_{CTX-M-2} gene found in two isolates was located on a complex class 1 integron. The *bla*_{DHA-1} gene was preceded by a transcriptional regulator gene and was followed by phage shock protein genes. The *bla*_{CTX-M} genes were located on the chromosome in 21 isolates. A plasmid location for the *bla*_{CTX-M} gene was found in only four isolates: the *bla*_{CTX-M-14a} gene was located on ~150-kbp IncA/C plasmids in three isolates and on a ~50-kbp IncN plasmid in one isolate. The *bla*_{TEM-52} gene was located on ~50-kbp IncN plasmids in all five isolates. The AmpC β -lactamase genes were located on the chromosome in seven of eight isolates; one isolate carried the *bla*_{CMY-2} gene on a ~150-kbp IncA/C plasmid. Our results show that a chromosomal location of CTX-M ESBL and AmpC β -lactamase genes in *P. mirabilis* is no longer an unusual phenomenon in hospital environments.

Proteus mirabilis is the second most common cause of urinary tract infections and an important cause of nosocomial infections (19). Oxyimino-cephalosporins have been used as the drugs of choice to treat infections caused by ampicillin-resistant *P. mirabilis*. However, as with other *Enterobacteriaceae*, *P. mirabilis* strains exhibiting resistance to expanded-spectrum β -lactam agents have been widely reported in many parts of the world (1, 5, 12, 18). Because *P. mirabilis* lacks species-specific chromosome-borne β -lactamases, resistance in this microorganism is wholly dependent on the acquisition of plasmid-encoded β -lactamases, such as extended-spectrum β -lactamases (ESBLs), AmpC enzymes, and metallo- β -lactamases (10, 15, 24).

Although uncommon, a chromosomal location for AmpC

and CTX-M ESBL genes in *P. mirabilis* has been reported. Since the first report of a clinical strain of *P. mirabilis* carrying a chromosomally encoded CMY-2-like enzyme, designated CMY-3 (3), *P. mirabilis* strains harboring chromosomal CMY-4, CMY-12, CMY-14, CMY-15, or CMY-16 from France, Italy, and Poland have been described (9, 10, 14). Two *P. mirabilis* strains carrying chromosomally encoded CTX-M ESBL, CTX-M-25 or CTX-M-41 have also been reported (17).

Here we report a high prevalence of clinical *P. mirabilis* isolates carrying the chromosome-borne *bla*_{CTX-M} and/or AmpC β -lactamase genes in Korea.

MATERIALS AND METHODS

Bacterial strains. In a nationwide survey conducted between July and September 2008, a total of 222 consecutive nonduplicate *P. mirabilis* isolates were collected from 17 hospitals in 11 cities in Korea. The isolates were recovered from urine (*n* = 138), blood (*n* = 10), respiratory specimens (*n* = 18), and pus (*n* = 56). The isolates were identified using a Vitek GNI card (bioMérieux, Marcy-l'Etoile, France).

* Corresponding author. Mailing address: Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, 120-752, 134 Shinchon-Dong, Seodaemun-Gu, Seoul, Republic of Korea. Phone: 82-2-2228-6096. Fax: 82-2-313-0908. E-mail: kscpjsh@yuhs.ac.

[∇] Published ahead of print on 31 January 2011.

TABLE 1. Sequences of PCR primers used in a genetic environment study

Name	Target gene	Sequence (5' to 3')
CTX-M1-mF	<i>bla</i> _{CTX-M-1} cluster	CGC GCT ACA GTA CAG CGA TA
CTX-M1-mR		AGC TTA TTC ATC GCC ACG TT
CTX-M2-mF	<i>bla</i> _{CTX-M-2} cluster	ACAGAGCGAGAGCGATAAGC
CTX-M2-mR		TATTGCCCTTAAGCCACGTC
CTX-M9-mF	<i>bla</i> _{CTX-M-9} cluster	ACG TGG CTC AAA GGC AAT AC
CTX-M9-mR		TCA ATT TGT TCA TGG CGG TA
CMY-2bF	<i>bla</i> _{CMY-2} cluster	GAT TAG GCT GGG AGA TGC TG
DHA-1F	<i>bla</i> _{DHA}	TTA CGG TCA TTA CGC CAC TG
DHA-mF		ATT TTC AGT GAC CGG CTG TT
DHA-fR		TAA TTC AGC GCA GAT TGT GG
DHA-mR		CAT TAA CGG TGT GAC CAA CG
DHA AmpR-mR		CAG GGT AAA GCG GTG AAC AT
IRL ISEcp1-F	ISEcp1-like	CCT AGA TTC TAC GTC AGT ACT
ISEcp1-F		TCA AAA
ISEcp1-R		TCT GCT CCT TGA GAA TGC AA
ISEcp1-bmF		TCG CCC AAA ATG ACT TTA GC
ISCR1-F	ISCR1	TCA AAG AAG CCA AAT ACG ACA
ISCR1-R		GCG AGT CAA TCG CCC ACT
ISCR1-mF		CGA CTC TGT GAT GGA TCG AA
ISCR1-pR		GAT GCC GAG AAT ACG TGG TT
IS903-F	IS903	CAG ACG CTC GTG ATG ACA AT
IS903-R		TGG CCC ACC TAC AAT AAA GC
IS903-bF		GGC ATA CCT GCT TTC GTC AT
IS903-mR		CTG TTC GGG GGT TCA CTG AC
pspA-fF	<i>pap</i>	CAG ATG CAG CTT ACG CCA TA
pspB-F		GCA TTG CCC GAT ATC AGA AC
pspD-mF		TAT TTC TGG CCA TCC CGT TA
pspB-mR		ACG TCC GCT AAA AAT GTT GC
pspD-bR		CGA CTG GAA CGA TTG CTG TA
Int11-F	<i>Int11</i>	TGC TTG CTT TTG TTG TTT CG
Int11-R		CCA AGC TCT CGG GTA ACA TC
5CS-R		CAT GAA AAC CGC CAC TGC
qacEΔ1-F	<i>qacEΔ1-sul1</i>	CTT AAG GAG GCT ACG GCT TTC
qacEΔ1-R		GAA AGG CTG GCT TTT TCT TG
3CS-mR		GCA GCG ACT TCC ACG ATG
sul1-F		TGT GAA AGG CGA GAT CAT CA
sul1-mF		TCA CCG AGG ACT CCT TCT TC
sul1-R		GGG TTT CCG AGA AGG TGA TT
orf1-F	<i>orf1</i>	ACG AGA TTG TGC GGT TCT TC
cat-F	<i>cat</i>	GCT GTT CGT CGC TTT CTC TT
cat-fF		CCA AAA GGA CAC GGA GAT GT
aadA1-mF	<i>aadA1</i>	AAG CAA GCT CAG GAG GTG AA
aadA1-fF		ACA TCA TTC CGT GGC GTT AT
aadA1-mR		AGG TCC GTT TTT GGT CAC AG
aadA1-fR		AGG TTT CAT TTA GCG CCT CA
ORF477-F	<i>orf477</i>	AGC CGA GGG AAG TTA AAA GC
ORF477-R		GAG CGA TAT GCA GCA ACA GA
blc-R	<i>blc</i>	GCA TAC CAG GCC ATA AGC TC
		GTA GGG GTC CGT GAA AGG AT

Antimicrobial susceptibility testing. The phenotypic confirmatory test for ESBL and/or AmpC β-lactamase production using boronic acid (BA) as an AmpC β-lactamase inhibitor was performed as described previously (21). MICs of β-lactams in the absence or presence of clavulanic acid (at a fixed concentration of 4 μg/ml; Sigma, St. Louis, MO) were determined by the agar dilution method according to CLSI guidelines (6).

Conjugal transfer experiments. The agar mating method was used to test the transferability of oxymino-cephalosporin resistance by using azide-resistant *Escherichia coli* J53 as a recipient (13). Transconjugants were selected on Mueller-Hinton agar plates supplemented with either 2 μg/ml ceftazidime, 2 μg/ml cefotaxime, or 8 μg/ml cefoxitin and 100 μg/ml sodium azide.

Characterization of genes encoding β-lactamases. Genes coding for ESBLs and AmpC β-lactamases were detected by PCR amplification as described previously (20, 22). The templates for PCR amplification in clinical isolates were whole-cell lysates, and the PCR products were subjected to direct sequencing. Both strands of the PCR products were sequenced twice with an automatic sequencer (model 3730xl; Applied Biosystems, Weiterstadt, Germany).

Analysis of the genetic environments surrounding the *bla* genes. The genetic organization of the *bla* genes of CTX-M and AmpC enzymes was investigated by PCR mapping and sequencing of the regions surrounding the genes by using the primers listed in Table 1.

PCR-based replicon typing of plasmids. Plasmid replicon typing of the isolates carrying genes encoding CTX-M ESBLs and/or AmpC β-lactamases was per-

formed using the PCR-base method with 18 pairs of primers described by Carattoli et al. (4).

Plasmid analysis. Plasmid DNA was purified from clinical *P. mirabilis* isolates using the NucleoBond Xtra Midi kit (Macherey-Nagel GmbH, Düren, Germany). Purified plasmids were digested with the restriction endonucleases HindIII, NdeI, and SpeI, and their restriction patterns were compared with one another by agarose gel electrophoresis.

PFGE and Southern blotting. Plugs containing whole genomic DNA of the *P. mirabilis* isolates were digested with SfiI, I-CeuI, and S1 nuclease separately. DNA fragments were separated by pulsed-field gel electrophoresis (PFGE) using a CHEF-DRII device (Bio-Rad, Hercules, CA). The PFGE conditions of SfiI macrorestriction analysis were 6 V/cm for 20 h, with pulse times ranging from 0.5 to 60 s, at a temperature of 14°C. Pulse times for I-CeuI and S1 nuclease restriction analysis were 9 to 90 s. DNA treated with I-CeuI or S1 nuclease was blotted onto a nylon membrane (Zeta-Probe blotting membranes; Bio-Rad) and was hybridized with probes specific for genes encoding AmpC β-lactamases or CTX-M ESBLs, various specific replicons, and 16S rRNA genes. The probes were obtained by PCR experiments as described above. Probe labeling, hybridization, and detection were performed with the DIG DNA labeling and detection kit (Roche Diagnostics, Indianapolis, IN) according to the manufacturer's protocols.

Nucleotide sequence accession number. The nucleotide sequence data for the *bla*_{CTX-M-90} gene are available in the GenBank nucleotide sequence database under accession no. GU065288.

RESULTS AND DISCUSSION

Prevalence and types of ESBLs and AmpCs. The phenotypic confirmatory test detected 28 (12.6%) ESBL producers and 8 (3.6%) AmpC producers among 222 *P. mirabilis* isolates (data not shown). Three isolates gave positive results for both an ESBL and an AmpC enzyme simultaneously. *P. mirabilis* isolates exhibiting the ESBL and AmpC phenotypes were recovered from 12 and 7 hospitals, respectively.

The most common type of class A ESBL gene identified using PCR and sequencing experiments was *bla*_{CTX-M-14a} (*n* = 12). The *bla*_{CTX-M-90} (*n* = 4), *bla*_{CTX-M-15} (*n* = 3), *bla*_{CTX-M-12} (*n* = 3), *bla*_{CTX-M-2} (*n* = 2), *bla*_{CTX-M-14b} (*n* = 1), *bla*_{TEM-52} (*n* = 5), and *bla*_{SHV-12} (*n* = 1) genes were also detected. Three isolates each carried two ESBL genes (Table 2). No *bla* genes of the PER, VE-, GES, or TLA type, or of the CTX-M-8 cluster, were detected in this survey.

Compared with that found by a survey carried out in 2004 (18), the prevalence of ESBL-producing *P. mirabilis* has increased from 9.7% to 12.6% in Korea. In 2004, 6.7% (9/134) of *P. mirabilis* clinical isolates were reported to produce CTX-M ESBLs, while in 2008, the prevalence of these enzymes showed a notable increase, reaching 11.3% (25/222). These results suggest that the significant increase in the incidence of ESBL-producing *P. mirabilis* has been due to the dissemination of strains producing CTX-M enzymes.

All eight isolates exhibiting the AmpC phenotype carried an AmpC β-lactamase gene, such as *bla*_{CMY-2} (*n* = 6) or *bla*_{DHA-1} (*n* = 2). Moreover, *bla* genes encoding ESBLs and AmpC β-lactamases were detected simultaneously in three isolates. The phenotypic characteristics of ESBL- and/or AmpC-producing isolates and their transconjugants are shown in Table 2.

Analysis of the genetic contexts of the *bla* genes. All *bla* genes encoding CTX-M-1- and CTX-M-9-type enzymes were preceded by ISEcp1-like elements (Fig. 1). The ISEcp1-like elements were observed 48 bp upstream of the open reading

TABLE 2. Characteristics of *P. mirabilis* isolates producing ESBLs and/or AmpC β -lactamases

Isolate	Hospital	Ward ^a	Specimen	β -Lactamase		CTX	CTX-CA	MIC (μ g/ml) ^b		
				ESBL	AmpC			CAZ	CAZ-CA	FOX
SSM6	Seoul-1	ER	Urine	TEM-52		8	<0.06	4	<0.06	2
SSM10	Seoul-1	GW	Pus	CTX-M-90, TEM-52		32	0.12	8	0.12	2
SSM12	Seoul-1	ER	Urine	CTX-M-14, SHV-12	DHA-1	32	0.25	16	0.12	16
trcSSM12				CTX-M-14		16	<0.06	0.25	<0.06	2
KN26	Seoul-2	GW	Urine	CTX-M-12		16	<0.06	2	<0.06	4
KN26	Seoul-2	GW	Urine		CMY-2	8	8	8	4	32
KN26	Seoul-2	GW	Pus		CMY-2	16	16	16	16	64
KDS43	Seoul-3	GW	Pus			32	0.12	0.5	0.12	4
YS126	Seoul-4	GW	Pus	CTX-M-12		64	0.12	4	0.5	2
YS132	Seoul-4	GW	Sputum	CTX-M-90, TEM-52		32	<0.06	16	0.25	2
trcYS132				TEM-52		32	<0.06	0.25	<0.06	4
YS143	Seoul-4	GW	Pus	CTX-M-14		32	<0.06	0.25	<0.06	4
JYS190	Seoul-5	GW	Pus	CTX-M-14		32	0.12	0.25	<0.06	2
JYS195	Seoul-5	GW	Pus	CTX-M-14		16	<0.06	0.25	<0.06	2
JYS201	Seoul-5	ER	Pus	CTX-M-14		16	<0.06	0.25	<0.06	4
JYS209	Seoul-6	GW	Pus	CTX-M-12		16	0.12	2	0.25	2
JHS214	Seoul-6	GW	Urine	CTX-M-15		32	<0.06	8	<0.06	4
JHS215	Seoul-6	ICU	Pus	CTX-M-14	CMY-2	32	16	4	4	32
JHS218	Seoul-6	ICU	Urine	CTX-M-14	CMY-2	16	16	4	16	32
trcJHS218					CMY-2	16	8	16	16	64
JHS222	Seoul-6	GW	Urine	CTX-M-14		32	<0.06	0.25	<0.06	2
MG63	Goyang	ER	Blood	CTX-M-14		32	<0.06	0.25	<0.06	2
trcMG63				CTX-M-14		16	<0.06	0.12	<0.06	2
MG67	Goyang	ICU	Blood		CMY-2	8	8	8	4	32
MG73	Goyang	GW	Pus	CTX-M-15		>128	<0.06	8	<0.06	2
MG74	Goyang	GW	Urine	CTX-M-15		128	0.12	4	0.12	2
MG77	Goyang	ER	Urine	CTX-M-14		32	<0.06	0.25	<0.06	8
BDC115	Sungnam	GW	Pus	CTX-M-14		32	0.12	0.5	0.12	4
WJCI61	Wonju	GW	Sputum	CTX-M-2		64	0.25	2	0.12	8
WJCI64	Wonju	GW	Urine	CTX-M-2		64	0.25	1	0.12	8
WJCI68	Wonju	GW	Urine		DHA-1	1	2	1	0.12	64
GM58	Daegu	ICU	Sputum		CMY-2	4	8	2	2	32
GS56	Jinju	GW	Sputum	CTX-M-14		32	0.12	2	0.12	4
PS79	Busan-1	ER	Blood	TEM-52		16	<0.06	32	<0.06	2
IJP86	Busan-2	GW	Pus	CTX-M-14		32	<0.06	0.12	<0.06	4
trcIJP86				CTX-M-14		16	<0.06	0.12	<0.06	2
IJP88	Busan-2	GW	Urine	TEM-52		32	<0.06	>128	<0.06	4
IJP92	Busan-2	ER	Urine	CTX-M-90		32	0.12	0.25	0.12	4
JJH178	Jeju	GW	Urine	CTX-M-90		128	0.25	0.25	<0.06	4

^a ER, emergency room; GW, general ward; ICU, intensive-care unit.
^b CTX, cefotaxime; CA, clavulanic acid; CAZ, ceftazidime; FOX, ceftoxitin.










Genotype	Genetic environment ()	Identical sequences (GenBank accession no.)	Isolate
<i>bla</i> _{TEM-52}		EF141186 (2,231 bp)	SSM6, SSM10, PS79, IJP88, YS132
<i>bla</i> _{SHV-12}		EU855787 (2,181 bp)	SSM12
<i>bla</i> _{CTX-M-1} type (<i>bla</i> _{CTX-M-12} and <i>bla</i> _{CTX-M-15})		DQ821704 (2,284 bp)	KNS26, MG73, MG74, YS126, JHS209, JHS214
<i>bla</i> _{CTX-M-2}		a. DQ520941 (4,632 bp) b. AY079169 (4,007 bp)	WJC161, WJC164
<i>bla</i> _{CTX-M-9} type (<i>bla</i> _{CTX-M-14a} , <i>bla</i> _{CTX-M-14b} , and <i>bla</i> _{CTX-M-90})		EU418916 (2,408 bp)	GS56, GM63, MG77, IJP86, IJP92, BDC115, YS132, YS143, JJH178, JYS201, JHS215, JHS218, JHS222
		AJ416341 (2,256 bp)	SSM10, SSM12, JYS190, JYS195
<i>bla</i> _{CMY-2}		AB525688 (4,234 bp)	KNS34, KDS43, GM58, MG67, JHS215, JHS218
<i>bla</i> _{DHA-1}		AJ971345 (5,446 bp)	SSM12, WJC168

FIG. 1. Schematic representation of the genetic environments surrounding the ESBL and AmpC genes in *Proteus mirabilis* clinical isolates. IRR, right inverted repeat sequences; IRL, left inverted repeat sequences.

frames (ORFs) encoding CTX-M-1-type enzymes or 42 bp upstream of the ORFs encoding CTX-M-9-type enzymes, as reported previously (11). The IS903-like element was detected downstream of the *bla*_{CTX-M-9}-type genes in 13 isolates (Fig. 1).

The *bla*_{CTX-M-14b} gene was first detected in *E. coli* strains isolated in Spain, and it exhibits three silent mutations compared with the *bla*_{CTX-M-14a} gene (16). Navarro et al. (16) reported that the *bla*_{CTX-M-14a} gene was associated with ISEcp1 and IS903 located on an IncK plasmid, whereas the *bla*_{CTX-M-14b} gene was associated with In60 located on an IncHI2 plasmid, like *bla*_{CTX-M-9}. In this study, one isolate (JY195) was found to contain a *bla*_{CTX-M-14b} gene, but it was linked to ISEcp1, like the *bla*_{CTX-M-14a} gene, and was located on the chromosome (see below).

The *bla*_{CTX-M-2} gene in two isolates was located on a complex class 1 integron. The 4,632-bp region from the 5' conserved segment (5'-CS) to the first copy of 3'-CS (3'-CS1) showed 100% homology with a class 1 integron previously characterized from a *P. mirabilis* strain (12). The 4,007-bp region from ISCR1 to the second copy of 3'-CS (3'-CS2) also showed 100% homology to that of an unusual class 1 integron, In35 (2) (Fig. 1).

The *bla*_{TEM-52} gene in all five isolates was preceded by resolvase (*tnpR*) and transposase (*tnpA*) genes identical to those of transposon Tn3 (7). The *bla*_{SHV-12} gene in isolate SSM12 was preceded by IS26 and was followed by a transcriptional regulator gene (*ygbI*), showing the same arrangement as that found on plasmid pE19 from an *Enterobacter cloacae* strain (GenBank accession no. GU205813) (Fig. 1).

The *bla*_{CMY-2} gene in all six isolates was also preceded by ISEcp1-like elements. The ISEcp1-like elements were observed 116 bp upstream of the ORF encoding the CMY-2 enzyme. The *bla*_{DHA-1} gene in two isolates was preceded by a transcriptional regulator gene (*ampR*) and followed by phage shock protein genes (*pspA*, *pspB*, *pspC*, and *pspD*), as reported previously (23) (Fig. 1).

Locations of the *bla* genes. Despite repeated attempts, transconjugants were obtained from only five isolates, with transfer of *bla*_{CTX-M-14} in three cases and of *bla*_{TEM-52} and *bla*_{DHA-1} in the remaining cases (Table 2). The probe specific for the *bla*_{CTX-M-14a} gene hybridized with a ~50-kbp IncN plasmid and ~150-kbp IncA/C plasmids in one and three isolates, respectively (Fig. 2). IncA/C plasmids carrying the *bla*_{CTX-M-14a} gene from three isolates exhibited restriction patterns identical to one another when digested with endonucleases of HindIII, NdeI, and SpeI (Fig. 3Ab). The probe specific for the *bla*_{TEM-52} gene hybridized with ~150-kbp IncA/C plasmids in all five isolates. The IncN plasmids also showed restriction patterns identical to one another (Fig. 3Bb). The probe specific for the *bla*_{CMY-2} gene hybridized with a ~50-kbp IncN plasmid in only one isolate. However, probes specific for the CTX-M and AmpC genes did not bind to any plasmids in the remaining isolates. Probes specific for CTX-M genes hybridized strongly with I-CeuI macrorestriction fragments (250 to >800 kbp) from 21 CTX-M ESBL-producing *P. mirabilis* isolates (2 isolates with CTX-M-2, 3 with CTX-M-12, 9 with CTX-M-14, 3 with CTX-M-15, and 4 with CTX-M-90). Furthermore, probes specific for the *bla*_{DHA-1} and *bla*_{CMY-2} genes also hybridized with I-CeuI macrorestriction fragments (450 to >800 kbp) from two and




FIG. 2. Dendrogram based on SfiI macrorestriction patterns of *P. mirabilis* isolates producing ESBLs and/or AmpC β -lactamases, indicating the similarity (expressed as a percentage) of PFGE profiles. Isolate SSM12 repeatedly failed to yield SfiI macrorestriction fragments. Three CTX-M-12-producing isolates showed >80% similarity, despite being recovered from three different hospitals, while other types of ESBL- or AmpC-producing isolates showed lower percentages of similarity. The locations of the bla genes of TEM-, SHV-, and CTX-M-type ESBLs and AmpC enzymes are given on the right.

five isolates, respectively. Finally, the hybridization of macrorestriction fragments with the probe specific for 16S rRNA genes confirmed the chromosomal location of the bla genes encoding CTX-M ESBLs and AmpC enzymes (data not shown).

Strain typing. Of 13 CTX-M-14-producing isolates, 1 (SSM12) repeatedly failed to yield SfiI macrorestriction fragments. Among 12 CTX-M-14-producing isolates, only 2 (JHS215 and JHS222), which were recovered from the same hospital, were clonally related to one another, with 80% similarity; others were not clonally related (Fig. 2).

Our results revealed that the spread of the bla_{CTX-M-14a} and bla_{TEM-52} genes among *P. mirabilis* might be driven by horizontal transfer of IncA/C and IncN plasmids, respectively. Notably, however, most of the CTX-M ESBL and AmpC β -lactamase genes were found on the chromosome and not on plasmids. A chromosomal location for CTX-M ESBL and AmpC β -lactamase genes in *Enterobacteriaceae* other than *P. mirabilis* has rarely been reported, though

Coque et al. (8) recently described eight *E. coli* clinical isolates carrying the chromosome-borne bla_{CTX-M-15} gene. In contrast to other species, *P. mirabilis* containing CTX-M ESBL and/or AmpC β -lactamase genes on the chromosomes has been reported uncommonly elsewhere. It is noteworthy that the chromosomal location of CTX-M ESBL and AmpC β -lactamase genes in *P. mirabilis* is no longer an unusual phenomenon in the hospital environment. Chromosomally located genes are surrounded by a genetic environment similar to that of plasmids, and this supports the idea that the CTX-M ESBL and AmpC β -lactamase genes are integrated into the chromosome via transposable elements in the *P. mirabilis* species.

In conclusion, the present data suggested that the incidence of ESBL-producing *P. mirabilis* has increased due to the dissemination of bla genes encoding CTX-M enzymes in Korea. The most common types of ESBL and AmpC β -lactamase in *P. mirabilis* were CTX-M-14 and CMY-2, respectively. Interestingly, these enzymes were chromosomally located in most *P.*




FIG. 3. (Aa) Banding patterns of S1 nuclease-digested linearized plasmids from three *P. mirabilis* clinical isolates carrying the *bla*_{CTX-M-14a} gene (lanes 1 to 3) and Southern blot analysis of plasmid DNA with a probe specific to the gene (lanes 4 to 6). (Ab) Restriction patterns of ~150-kbp plasmids carrying the *bla*_{CTX-M-14a} gene digested with the HindIII, NdeI, or SpeI restriction endonuclease (lanes 7 to 9) and Southern blot analysis of plasmid DNA with a probe specific to the gene (lanes 10 to 12). (Ba) Banding patterns of S1 nuclease-digested linearized plasmids from five *P. mirabilis* clinical isolates carrying the *bla*_{TEM-52} gene (lanes 1 to 5) and Southern blot analysis of plasmid DNA with a probe specific to the gene (lanes 6 to 10). (Bb) Restriction patterns of ~50-kbp plasmids carrying the *bla*_{TEM-52} gene (lanes 11 to 15) and Southern blot analysis of plasmid DNA with a probe specific to the gene (lanes 16 to 20). Lanes M1, Lambda ladder (Promega Co., Madison, WI); lanes M2, 500-bp DNA ladder (Takara Inc., Tokyo, Japan).

mirabilis isolates. The mechanism and significance of this phenomenon need to be elucidated.

ACKNOWLEDGMENTS

This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MEST) (2009-0071195) and by a research grant from the Korea Center for Disease Control (2009-E00520-00).

REFERENCES

1. Aragón, L. M., et al. 2008. Increase in β -lactam-resistant *Proteus mirabilis* strains due to CTX-M- and CMY-type as well as new VEB- and inhibitor-resistant TEM-type β -lactamases. *J. Antimicrob. Chemother.* **61**:1029–1032.
2. Arduino, S. M., et al. 2002. *bla*_{CTX-M-2} is located in an unusual class 1 integron (In35) which includes orf513. *Antimicrob. Agents Chemother.* **46**:2303–2306.
3. Bret, L., et al. 1998. Chromosomally encoded AmpC-type β -lactamase in a clinical isolate of *Proteus mirabilis*. *Antimicrob. Agents Chemother.* **42**:1110–1114.
4. Carattoli, A., et al. 2005. Identification of plasmids by PCR-based replicon typing. *J. Microbiol. Methods* **63**:219–228.
5. Chanal, C., et al. 2000. Prevalence of β -lactamases among 1,072 clinical isolates of *Proteus mirabilis*: a 2-year survey in a French hospital. *Antimicrob. Agents Chemother.* **44**:1930–1935.
6. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing; seventeenth informational supplement. M7–A8. CLSI, Wayne, PA.
7. Cloeckaert, A., et al. 2007. Dissemination of an extended-spectrum β -lactamase *bla*_{TEM-52} gene carrying IncII plasmid in various *Salmonella enterica* serovars isolated from poultry and humans in Belgium and France between 2001 and 2005. *Antimicrob. Agents Chemother.* **51**:1872–1875.
8. Coque, T. M., et al. 2008. Dissemination of clonally related *Escherichia coli* strains expressing extended-spectrum β -lactamase CTX-M-15. *Emerg. Infect. Dis.* **14**:195–200.
9. D'Andrea, M. M., et al. 2006. CMY-16, a novel acquired AmpC-type β -lactamase of the CMY/LAT lineage in multifocal monophyletic isolates of *Proteus mirabilis* from Northern Italy. *Antimicrob. Agents Chemother.* **50**:618–624.
10. Decré, D., et al. 2002. Characterization of CMY-type β -lactamases in clinical strains of *Proteus mirabilis* and *Klebsiella pneumoniae* isolated in four hospitals in the Paris area. *J. Antimicrob. Chemother.* **50**:681–688.
11. Eckert, C., V. Gautier, and G. Arlet. 2006. DNA sequence analysis of the genetic environment of various *bla*_{CTX-M} genes. *J. Antimicrob. Chemother.* **57**:14–23.
12. Gionechetti, F., et al. 2008. Characterization of antimicrobial resistance and class 1 integrons in *Enterobacteriaceae* isolated from Mediterranean herring gulls (*Larus cachinnans*). *Microb. Drug Resist.* **14**:93–99.
13. Jacoby, G. A., and P. Han. 1996. Detection of extended-spectrum β -lactamases in clinical isolates of *Klebsiella pneumoniae* and *Escherichia coli*. *J. Clin. Microbiol.* **34**:908–911.
14. Literacka, E., et al. 2004. Four variants of the *Citrobacter freundii* AmpC-type cephalosporinases, including novel enzymes CMY-14 and CMY-15, in a *Proteus mirabilis* clone widespread in Poland. *Antimicrob. Agents Chemother.* **48**:4136–4143.
15. Luzzaro, F., et al. 2009. Spread of multidrug-resistant *Proteus mirabilis* isolates producing an AmpC-type β -lactamase: epidemiology and clinical management. *Int. J. Antimicrob. Agents* **33**:328–333.
16. Navarro, F., et al. 2007. Evidence for convergent evolution of CTX-M-14 ESBL in *Escherichia coli* and its prevalence. *FEMS Microbiol. Lett.* **273**:120–123.
17. Navon-Venezia, S., I. Chmelnitsky, A. Leavitt, and Y. Carmeli. 2008. Dissemination of the CTX-M-25 family β -lactamases among *Klebsiella pneumoniae*, *Escherichia coli* and *Enterobacter cloacae* and identification of the novel enzyme CTX-M-41 in *Proteus mirabilis* in Israel. *J. Antimicrob. Chemother.* **62**:289–295.
18. Park, Y. J., et al. 2006. Occurrence of extended-spectrum β -lactamases and plasmid-mediated AmpC β -lactamases among Korean isolates of *Proteus mirabilis*. *J. Antimicrob. Chemother.* **57**:156–158.
19. Rózsalski, A., Z. Sidorezyk, and K. Kotelko. 1997. Potential virulence factors of *Proteus* bacilli. *Microbiol. Mol. Biol. Rev.* **61**:65–89.
20. Ryoo, N. H., et al. 2005. Dissemination of SHV-12 and CTX-M-type extended-spectrum β -lactamases among clinical isolates of *Escherichia coli* and *Klebsiella pneumoniae* and emergence of GES-3 in Korea. *J. Antimicrob. Chemother.* **56**:698–702.
21. Song, W., et al. 2007. Use of boronic acid disk methods to detect the combined expression of plasmid-mediated AmpC β -lactamases and extended-spectrum β -lactamases in clinical isolates of *Klebsiella* spp., *Salmonella* spp., and *Proteus mirabilis*. *Diagn. Microbiol. Infect. Dis.* **57**:315–318.
22. Song, W., et al. 2006. Increasing trend in the prevalence of plasmid-mediated AmpC β -lactamases in *Enterobacteriaceae* lacking chromosomal *ampC* gene at a Korean university hospital from 2002 to 2004. *Diagn. Microbiol. Infect. Dis.* **55**:219–224.
23. Verdet, C., et al. 2006. Emergence of DHA-1-producing *Klebsiella* spp. in the Parisian region: genetic organization of the *ampC* and *ampR* genes originating from *Morganella morganii*. *Antimicrob. Agents Chemother.* **50**:607–617.
24. Vourli, S., et al. 2006. Emergence of *Proteus mirabilis* carrying the *bla*_{VIM-1} metallo- β -lactamase gene. *Clin. Microbiol. Infect.* **12**:691–694.